These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30753228)

  • 1. Novel site-specific PEGylated L-asparaginase.
    Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of a novel N-terminal PEGylated crisantaspase.
    Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncovalent PEGylation of L-asparaginase using PEGylated polyelectrolyte.
    Kurinomaru T; Shiraki K
    J Pharm Sci; 2015 Feb; 104(2):587-92. PubMed ID: 25354692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
    Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
    Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line.
    Costa IM; Effer B; Costa-Silva TA; Chen C; Ciccone MF; Pessoa A; Dos Santos CO; Monteiro G
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
    Schnuchel A; Radcke C; Theobald L; Doeding S
    PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials.
    Viña-Romero MM; Ramos Díaz R; González García J; Nazco-Casariego G; Díaz-Vera J; Gutiérrez-Nicolás F
    J Oncol Pharm Pract; 2021 Jul; 27(5):1102-1105. PubMed ID: 32854574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparaginase activities during intensified treatment with pegylated
    Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
    Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
    Patel N; Krishnan S; Offman MN; Krol M; Moss CX; Leighton C; van Delft FW; Holland M; Liu J; Alexander S; Dempsey C; Ariffin H; Essink M; Eden TO; Watts C; Bates PA; Saha V
    J Clin Invest; 2009 Jul; 119(7):1964-73. PubMed ID: 19509471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
    Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
    Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
    Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
    Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
    Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
    Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
    Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
    Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
    Asselin BL; Ryan D; Frantz CN; Bernal SD; Leavitt P; Sallan SE; Cohen HJ
    Cancer Res; 1989 Aug; 49(15):4363-8. PubMed ID: 2743326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase.
    Rodrigues MAD; Pimenta MV; Costa IM; Zenatti PP; Migita NA; Yunes JA; Rangel-Yagui CO; de Sá MM; Pessoa A; Costa-Silva TA; Toyama MH; Breyer CA; de Oliveira MA; Santiago VF; Palmisano G; Barbosa CMV; Hebeda CB; Farsky SHP; Monteiro G
    Biochem Pharmacol; 2020 Dec; 182():114230. PubMed ID: 32979352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.